Jango to manage Grünenthal pain awards
pharmafile | February 3, 2011 | News story | Medical Communications | Grunenthal, Jango, awards, disease awareness campaigns
Jango Communications has been appointed by Grünenthal to manage the Pain Awards Programme they are sponsoring this year.
German-based Grünenthal, who set-up a UK office six years ago and specialise in pain management, chose Jango to support the programme which culminates in Edinburgh at the British Pain Society Annual Congress on 21 June.
The aim of the pain awards ceremony is to raise the standard of patient care and to share best practice by supporting projects being carried out around the country that might otherwise go unrecognised.
The awards are designed to allow individuals and/or groups of professionals across disciplines, to submit projects in pain management. The projects are required to show innovation and a significant contribution to raising the standard of patient care.
Maggie Malpas Spencer, managing director at Jango, commented: “This is a wonderful opportunity for Jango to be involved in a programme that has such a significant impact on well-being of patients within the field of pain management. We are also delighted to work with a company that demonstrates its commitment to enhancing the lives of patients.”
Chris Matijasevic, managing director at Grünenthal, said the company are delighted to be a part of the awards and added: “It is a great pleasure that we at Grünenthal have the opportunity to support an awards programme that identifies and rewards projects within pain management that would otherwise go unrecognised. We are pleased that Jango are able to support us in ensuring the Awards programme will be a huge success.”
Brett Wells
Related Content
Winners announced for 2025 PM Society Awards
The pharma marketing and healthcare communications industry gathered for the 39th PM Society Awards on …
PharmaTimes Medical & Scientific Excellence Awards and Nursing Industry Excellence Awards are open for entry
Both awards are open for entry until 17 May 2024 and the live awards ceremony …
Grünenthal receives FDA Breakthrough Therapy Designation for knee osteoarthritis drug
German pharmaceutical company Grünenthal has announced that the US Food and Drug Administration (FDA) has …
